PMID- 33824598 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 1178-7007 (Print) IS - 1178-7007 (Electronic) IS - 1178-7007 (Linking) VI - 14 DP - 2021 TI - Assessing MicroRNA-375 Levels in Type 2 Diabetes Mellitus (T2DM) Patients and Their First-Degree Relatives with T2DM. PG - 1445-1451 LID - 10.2147/DMSO.S298735 [doi] AB - PURPOSE: The pancreatic islet specific microRNA-375 (miR-375) is overexpressed in type 2 diabetes mellitus (T2DM) patients suppressing the glucose-induced insulin secretion. Thus, miR-375 may serve as a biomarker for the early prediction of T2DM among high-risk individuals. We conducted this clinical study to assess the significance of miR-375 among type 2 diabetes mellitus (T2DM) patients and their first-degree relatives. PATIENTS AND METHODS: We included 56 Han Chinese individuals (N: NGT = 21, T2DM = 10, FD-NGT =13 and FD-T2DM = 12) who received medical health check-ups from January 2018 to September 2018 at The Third Hospital of Yunnan Province, China. They were categorized as normal glucose tolerance (NGT), T2DM, first-degree relatives with normal glucose tolerance (FD-NGT) and first-degree relatives with T2DM (FD-T2DM). OGTT, C-peptide and Insulin tests were performed to confirm the diagnosis. The miR-375 levels were determined by Quantitative real-time RT-PCR (qRT-PCR). RESULTS: The OGTT test showed a significant difference in T2DM and FD-T2DM groups compared with NGT and FD-NGT (p< 0.05). Similar results were observed during C-peptide and insulin tests. Interestingly, the 2-hour insulin test showed FD-NGT group having a significantly higher mean +/- standard error of (64.240 +/- 12.775) compared to NGT (28.836 +/- 10.875). Assessment of miR-375 expression levels in 4 groups showed a significant up-regulation in T2DM and FD-T2DM compared with NGT and FD-NGT groups. A slight increase in miRNA expression was observed in FD-NGT compared with NGT group but was not statistically significant. CONCLUSION: The OGTT, C-peptide and insulin tests revealed a statistically significant difference in T2DM and FD-T2DM compared with NGT and FD-NGT groups. A significantly higher miR-375 expression was also observed in T2DM and FD-T2DM groups compared with NGT and FD-NGT and thus, miR-375 may serve as a stable biomarker for the early prediction of T2DM among high-risk individuals. CI - (c) 2021 Wu et al. FAU - Wu, Xu AU - Wu X AD - The Third People's Hospital of Yunnan Province, Department of Clinical Laboratory, Kunming, 650200, People's Republic of China. FAU - Li, Yashan AU - Li Y AD - The Third People's Hospital of Yunnan Province, Department of Clinical Laboratory, Kunming, 650200, People's Republic of China. FAU - Man, Baohua AU - Man B AD - The Third People's Hospital of Yunnan Province, Department of Clinical Laboratory, Kunming, 650200, People's Republic of China. FAU - Li, Dexuan AU - Li D AD - The Third People's Hospital of Yunnan Province, Department of Clinical Laboratory, Kunming, 650200, People's Republic of China. LA - eng PT - Journal Article DEP - 20210329 PL - New Zealand TA - Diabetes Metab Syndr Obes JT - Diabetes, metabolic syndrome and obesity : targets and therapy JID - 101515585 PMC - PMC8018570 OTO - NOTNLM OT - C-peptide OT - OGTT OT - insulin OT - microRNA-375 OT - type 2 diabetes mellitus COIS- All authors declare that they have no competing financial interests and report no conflicts of interest in this work. EDAT- 2021/04/08 06:00 MHDA- 2021/04/08 06:01 PMCR- 2021/03/29 CRDT- 2021/04/07 06:23 PHST- 2020/12/23 00:00 [received] PHST- 2021/03/04 00:00 [accepted] PHST- 2021/04/07 06:23 [entrez] PHST- 2021/04/08 06:00 [pubmed] PHST- 2021/04/08 06:01 [medline] PHST- 2021/03/29 00:00 [pmc-release] AID - 298735 [pii] AID - 10.2147/DMSO.S298735 [doi] PST - epublish SO - Diabetes Metab Syndr Obes. 2021 Mar 29;14:1445-1451. doi: 10.2147/DMSO.S298735. eCollection 2021.